ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2017
Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection.
Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Naringenin-Loaded PCL Nanoparticles Attenuate Glial Activation and TNF-α Expression in Iron-Induced Post-traumatic Epilepsy.Neurochemical research · 2026Article
- Anti-inflammatory potential of quercetin: From chemistry and mechanistic insight to nanoformulations.Current research in pharmacology and drug discovery · 2025Review
- Challenges and prospects in geriatric epilepsy treatment: the role of the blood-brain barrier in pharmacotherapy and drug delivery.Frontiers in aging neuroscience · 2024Review
- Novel Developments to Enable Treatment of CNS Diseases with Targeted Drug Delivery.Pharmaceutics · 2023Review
- Strategies for delivering therapeutics across the blood-brain barrier.Nature reviews. Drug discovery · 2021Review
- The Prospect of Nanoparticle Systems for Modulating Immune Cell Polarization During Central Nervous System Infection.Frontiers in immunology · 2021Article
- HIV Neuroinflammation: The Role of Exosomes in Cell Signaling, Prognostic and Diagnostic Biomarkers and Drug Delivery.Frontiers in cell and developmental biology · 2021Review
- Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders.Pharmaceutics · 2020Review
- State of the Mind: Growing up with HIV.Paediatric drugs · 2020Review
- Extracellular Vesicles as Drug Delivery Vehicles to the Central Nervous System.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Review
- Strategies for the use of Extracellular Vesicles for the Delivery of Therapeutics.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Review
- An Elvitegravir Nanoformulation Crosses the Blood-Brain Barrier and Suppresses HIV-1 Replication in Microglia.Viruses · 2020Article
- Article
- A novel kit for early diagnosis of Alzheimer's disease using a fluorescent nanoparticle imaging.Scientific reports · 2019Article
- Proceedings of the 2017 ISEV symposium on "HIV, NeuroHIV, drug abuse, & EVs".Journal of neurovirology · 2017Article
- Magnetically triggered drug release from nanoparticles and its applications in anti-tumor treatment.Drug delivery · 2017Article
- The role of nanotechnology in the treatment of viral infections.Therapeutic advances in infectious disease · 2017Review
- Nanomedicines for the Treatment of CNS Diseases.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2017Article
- Emerging roles of extracellular vesicles in neurodegenerative disorders: focus on HIV-associated neurological complications.Cell death & disease · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Despite the significant advances in neurological medicine, it remains difficult to treat ailments directly involving the brain. The blood brain barrier (BBB) is a tightly regulated, selectively permeable barrier that restricts access from the blood into the brain extracellular fluid (BEF). Many conditions such as tumors or infections in the brain are difficult to treat due to the fact that drugs and other therapeutic agents are unable to easily pass through this relatively impermeable barrier. Human Immunodeficiency Virus (HIV) presents a particular problem as it is able to remain dormant in the brain for years protected from antiretroviral drugs by the BBB. The development of nanoscale carriers over the past few decades has made possible the delivery of therapies with the potential to overcome membrane barriers and provide specific, targeted delivery. This review seeks to provide a comprehensive overview of the various aspects of nanoparticle formulation and their applications in improving the delivery efficiency of drugs, specifically antiretroviral therapeutics to the brain to treat HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.